Margarita Tokar

Ben-Gurion University of the Negev — Israel

Biochemistry, Genetics and Molecular Biology · Life Sciences

10h-index345citations41works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Breast Cancer Treatment Studies(20), Advanced Breast Cancer Therapies(11), HER2/EGFR in Cancer Research(9), Cancer Treatment and Pharmacology(5), Cancer Genomics and Diagnostics(4)

Publications41 total

Abstract PO5-01-08: The impact of Human Epidermal growth factor Receptor 2 (HER2) expression by RT-PCR on tumor characteristics and outcome in estrogen receptor (ER) positive, HER2 negative early-stage breast cancer
Cancer Research·2024
Stage I Breast Cancer in the Modern Era: A Retrospective Cohort Study of 328 Patients Diagnosed from 2002 to 2006 with a 14-Year Median Follow-Up
Oncology·2024
Stage I (T1N0M0) breast cancer with a median follow-up of 14 years: A retrospective cohort study of 328 consecutive patients and the prognostic value of tumor size, grade, and subtype
Research Square (Research Square)·2023Open Access
Second breast cancer: recurrence score results, clinicopathologic characteristics, adjuvant treatments, and outcomes—exploratory analysis of the Clalit registry
npj Breast Cancer·2023· 3 citedOpen Access
Clinical outcomes in estrogen receptor-positive early-stage breast cancer patients with Recurrence Score 26-30: observational real-world cohort study
npj Breast Cancer·2023· 4 citedOpen Access
Safety and rapid response of dabrafenib and trametinib therapy during hyperbilirubinemia in metastatic melanoma
Frontiers in Oncology·2023· 4 citedOpen Access
149P Clinical outcomes in ER+ breast cancer patients with recurrence score 26-30-guided therapy: Real-world data
Annals of Oncology·2022· 2 cited
Recurrence Score (RS) results, clinicopathologic characteristics, treatments, and outcomes in primary versus subsequent breast cancer (BC): Exploratory analysis of the Clalit Health Services (CHS) registry.
Journal of Clinical Oncology·2022
Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases
JAMA Oncology·2022· 20 citedOpen Access
Neoadjuvant therapy with doxorubicin-cyclophosphamide followed by weekly paclitaxel in early breast cancer: a retrospective analysis of 200 consecutive patients treated in a single center with a median follow-up of 9.5 years
Breast Cancer Research and Treatment·2022· 4 cited
Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer
Cancers·2022· 43 citedOpen Access
Abstract P1-08-14: Differences in Recurrence Score (RS) results between primary and second primary breast cancer (BC): Exploratory analysis of the Clalit Health Services (CHS) registry
Cancer Research·2022
Neoadjuvant Therapy with Doxorubicin-Cyclophosphamide Followed by Weekly Paclitaxel in Early Breast Cancer: A Retrospective Analysis of 200 Consecutive Patients Treated in A Single Center with A Median Follow-Up of 9.5 Years.
2022· 1 citedOpen Access
Recurrence score (RS) differences between primary and second-primary breast cancer (BC): Exploratory analysis of the Clalit Health Services (CHS) registry.
Journal of Clinical Oncology·2020
Ethnicity, recurrence score distribution, and clinical outcomes in ER + HER2‐negative breast cancer patients in Israel: A registry analysis
The Breast Journal·2020· 2 cited
Vismodegib as First-Line Treatment of Mutated Sonic Hedgehog Pathway in Adult Medulloblastoma
JCO Precision Oncology·2020· 12 citedOpen Access
Hypercalcemia as a Rebound Phenomenon of LOXO-292 Efficacy in Medullary Thyroid Cancer
JTO Clinical and Research Reports·2020· 1 citedOpen Access
Abstract P1-10-16: Ethnicity, recurrence score (RS) distribution, and clinical outcomes in ER+ HER2-negative breast cancer (BC) patients (pts) in Israel
Cancer Research·2020
Ten-year clinical outcomes in N0 ER+ breast cancer patients with Recurrence Score-guided therapy
npj Breast Cancer·2019· 27 citedOpen Access
Ten-year clinical outcomes in >1000 node-negative (N0) Estrogen Receptor (ER)+ breast cancer (BC) patients (Pts) where treatment decisions incorporated the Recurrence Score Results: a registry analysis using TAILORx categorization
The Breast·2019· 2 cited
page 1 of 3Next →

Frequent Co-authors

David Geffen(18), Michael Koretz(12), Samuel Ariad(12), Salomon M. Stemmer(11), Rinat Yerushalmi(10), Michelle Leviov(10), Bertha Delgado(9), Lior Soussan‐Gutman(9), Avital Bareket‐Samish(9), Amir Sonnenblick(9), Shani Paluch–Shimon(8), Sara Abu‐Ghanem(7), Michael Bayme(7), Georgeta Fried(7), Noa Ben Baruch(7), Efraim Idelevich(6), Hanoch Kashtan(6), Yoram Klein(6), Victor Buevich(6), Michael Dinerman(6)